Pre-hospital administration of tirofiban in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: a sub-analysis of the On-Time 2 trial.

AIMS Glycoprotein IIb/IIIa blocking agents seem to improve percutaneous coronary intervention (PCI) results in patients with ST-elevation myocardial infarction (STEMI). We aimed to compare the effect of pre-hospital administration of tirofiban in STEMI patients with and without diabetes mellitus (DM) treated with primary PCI. METHODS AND RESULTS We performed a pre-specified sub-analysis of the randomised On-Time II trial (n=984) and it's open label run-in phase (n=414), which investigated pre-hospital administration of high dose tirofiban in STEMI patients treated with primary PCI. Two-hundred and twenty (16%) diabetic patients (known DM or Hba1C ≥6.2%) were included, 101 in the placebo group and 119 in the tirofiban group. In patients with DM, randomisation to tirofiban resulted in a lower residual ST deviation (5.1±8.5 mm vs. 6.2±5.6 mm, p=0.003), a reduced infarct size (CK 1694±1925 U/L vs. CK 2040±1829 U/L, p=0.02) and a trend towards lower one-year mortality (4.6% vs. 11.6%, p=0.07). The beneficial effects of tirofiban were more pronounced in diabetic patients compared to patients without diabetes. CONCLUSIONS Pre-hospital administration of tirofiban in diabetic STEMI patients treated with primary PCI improves ST resolution and reduces myocardial infarct size. Tirofiban seems particularly beneficial in patients with diabetes.

[1]  E. Antman,et al.  Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38 , 2008, Circulation.

[2]  J. Ottervanger,et al.  Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial , 2008, The Lancet.

[3]  Diagnostic value of glycated haemoglobin (HbA1c) for the early detection of diabetes in high‐risk subjects , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[4]  G. Biondi-Zoccai,et al.  Early glycoprotein IIb–IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis , 2008, Heart.

[5]  A. Schmaier,et al.  Sweet and sticky: diabetic platelets, enhanced reactivity, and cardiovascular risk. , 2007, Journal of the American College of Cardiology.

[6]  Christopher P Cannon,et al.  Diabetes and mortality following acute coronary syndromes. , 2007, JAMA.

[7]  R. Gibbons,et al.  Comparison of myocardial reperfusion in patients undergoing percutaneous coronary intervention in ST-segment elevation acute myocardial infarction with versus without diabetes mellitus (from the EMERALD Trial). , 2007, The American journal of cardiology.

[8]  C. Granger,et al.  Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis-2 trial. , 2007, Archives of internal medicine.

[9]  S. Dharmage,et al.  HbA1c as a screening tool for detection of Type 2 diabetes: a systematic review , 2007 .

[10]  E. Vicaut,et al.  Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. , 2007, European heart journal.

[11]  C. Macaya,et al.  Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. , 2006, Journal of the American College of Cardiology.

[12]  J. Ottervanger,et al.  Prognostic significance of residual cumulative ST-segment deviation after mechanical reperfusion in patients with ST-segment elevation myocardial infarction. , 2005, American heart journal.

[13]  C. Macaya,et al.  Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. , 2005, Diabetes.

[14]  J. Ottervanger,et al.  Comparison of myocardial perfusion after successful primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction with versus without diabetes mellitus. , 2005, The American journal of cardiology.

[15]  J. Gore,et al.  Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. , 2004, Archives of internal medicine.

[16]  H. Hod,et al.  Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction , 2004, Circulation.

[17]  J. Ottervanger,et al.  Long-term, cause-specific mortality after myocardial infarction in diabetes. , 2004, European heart journal.

[18]  R. Nesto,et al.  The platelet in diabetes: focus on prevention of ischemic events. , 2003, Diabetes care.

[19]  J. Boura,et al.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction : a quantitative review of 23 randomised trials , 2022 .

[20]  G. Musumeci,et al.  Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty. , 2003, European heart journal.

[21]  Seung‐Jung Park,et al.  Effect of abciximab on myocardial salvage in patients with acute myocardial infarction undergoing primary angioplasty. , 2002, American Journal of Cardiology.

[22]  M. Noc,et al.  Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty. , 2002, The American journal of cardiology.

[23]  J. Killian,et al.  Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. , 2002, Journal of the American College of Cardiology.

[24]  A. Hamsten,et al.  Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study , 2002, The Lancet.

[25]  H. Suryapranata,et al.  Influence of prehospital administration of aspirin and heparin on initial patency of the infarct-related artery in patients with acute ST elevation myocardial infarction. , 2002, Journal of the American College of Cardiology.

[26]  C. Cannon,et al.  Importance of TIMI 3 flow. , 2001, Circulation.

[27]  Felix Zijlstra,et al.  Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction , 1997, The Lancet.

[28]  K. Mann,et al.  Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. , 1991, Annals of internal medicine.